Personalized Combined Modality Therapy for Locally Advanced Non-small Cell Lung Cancer

키워드

참고문헌 (73)

1. Kim DW, "Combined modality therapy for non-small cell lung cancer, past, present, and future", Lung Cancer, 42(Suppl 2), pp.S35~S40 (2003)
2. Subramanian J, "Review of ongoing clinical trials in non-small cell lung cancer: a status report for 2009 from the ClinicalTrials. gov website", J Thorac Oncol, 5, pp.1116~1119 (2010)
3. Mason KA, "Biology-based combined-modality radiotherapy : workshop report", Int J Radiat Oncol Biol Phys, 50, pp.1079~1089 (2001)
4. Belani CP, "Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer : a randomized phase II locally advanced multi-modality protocol", J Clin Oncol, 23, pp.5883~5891 (2005)
5. Mendelsohn J, "Epidermal growth factor receptor family and chemosensitization", J Natl Cancer Inst, 89, pp.341~343 (1997)
6. Schmidt-Ullrich RK, "Signal transduction and cellular radiation responses", Radiat Res, 153, pp.245~257 (2000)
7. Liang K, "The epidermal growth factor receptor mediates radioresistance", Int J Radiat Oncol Biol Phys, 57, pp.246~254 (2003)
8. Huguenin P, "Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy", J Clin Oncol, 22, pp.4665~4673 (2004)
9. Dickstein BM, "Increased resistance to cytotoxic agents in ZR75B human breast cancer cells transfected with epidermal growth factor receptor", Mol Cell Endocrinol, 110, pp.205~211 (1995)
10. Harari PM, "Biology of interactions : antiepidermal growth factor receptor agents", J Clin Oncol, 25, pp.4057~4065 (2007)
11. Huang SM, "Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck", Cancer Res, 59, pp.1935~1940 (1999)
12. Huang SM, "Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas : inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis", Clin Cancer Res, 6, pp.2166~2174 (2000)
13. Milas L, "In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody", Clin Cancer Res, 6, pp.701~708 (2000)
14. Lammering G, "EGFRvIII-mediated radioresistance through a strong cytoprotective response", Oncogene, 22, pp.5545~5553 (2003)
15. Baselga J, "Phase I studies of antiepidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin", J Clin Oncol, 18, pp.904~914 (2000)
16. Robert F, "Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer", J Clin Oncol, 19, pp.3234~3243 (2001)
17. Tuccillo C, "Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor", Clin Cancer Res, 11, pp.1268~1276 (2005)
18. Bonner JA, "Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck", N Engl J Med, 354, pp.567~578 (2006)
19. Harari PM, "Radiation combined with EGFR signal inhibitors : head and neck cancer focus", Semin Radiat Oncol, 16, pp.38~44 (2006)
20. Kelly K, "Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer : SWOG S0023", J Clin Oncol, 26, pp.2450~2456 (2008)
21. Blumenschein GR Jr, "Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA", B non-small-cell lung cancer : RTOG 0324, 2011, pp.29, 2312~2318
22. Govindan R, "Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer : Cancer and Leukemia Group B trial 30407", J Clin Oncol, 29, pp.3120~3125 (2011)
23. "J Clin Oncol", 2003, 2237~2246
24. Kris MG, "Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer : a randomized trial", JAMA, 290, pp.2149~2158 (2003)
25. Giaccone G, "Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer : a phase III trial--INTACT 1", J Clin Oncol, 22, pp.777~784 (2004)
26. Herbst RS, "Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer : a phase III trial--INTACT 2", J Clin Oncol, 22, pp.785~794 (2004)
27. Lynch TJ, "Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib", N Engl J Med, 350, pp.2129~2139 (2004)
28. Paez JG, "EGFR mutations in lung cancer : correlation with clinical response to gefitinib therapy", Science, 304, pp.1497~1500 (2004)
29. Ready N, "Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis : cancer and leukemia group B(CALEB)30106, a CALGB-stratified phase II trial", J Thorac Oncol, 5, pp.1382~1390 (2010)
30. Choong NW, "Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer", J Thorac Oncol, 3, pp.1003~1011 (2008)
31. Gatzemeier U, "Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer : the Tarceva Lung Cancer Investigation Trial", J Clin Oncol, 25, pp.1545~1552 (2007)
32. Herbst RS, "TRIBUTE : a phase III trial of erlotinib hydrochloride(OSI-774)combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer", J Clin Oncol, 23, pp.5892~5899 (2005)
33. Shepherd FA, "Erlotinib in previously treated non-small-cell lung cancer", N Engl J Med, 353, pp.123~132 (2005)
34. Janne PA, "Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin", paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406, 2010, pp.28(15s), 7503~
35. Coudert B, "Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer(NSCLC)according to response to first-line chemotherapy", Ann Oncol, 23, pp.388~394 (2012)
36. Mauceri HJ, "Combined effects of angiostatin and ionizing radiation in antitumour therapy", Nature, 394, pp.287~291 (1998)
37. Jain RK, "Normalization of tumor vasculature : an emerging concept in antiangiogenic therapy", Science, 307, pp.58~62 (2005)
38. Willett CG, "Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer", Nat Med, 10, pp.145~147 (2004)
39. Garcia-Barros M, "Tumor response to radiotherapy regulated by endothelial cell apoptosis", Science, 300, pp.1155~1159 (2003)
40. Mazeron R, "Current state of knowledge regarding the use of antiangiogenic agents with radiation therapy", Cancer Treat Rev, 37, pp.476~486 (2011)
41. Kim DW, "Molecular strategies targeting the host component of cancer to enhance tumor response to radiation therapy", Int J Radiat Oncol Biol Phys, 64, pp.38~46 (2006)
42. Bao S, "Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor", Cancer Res, 66, pp.7843~7848 (2006)
43. Zips D, "Triple angiokinase inhibition, tumour hypoxia and radiation response of FaDu human squamous cell carcinomas", Radiother Oncol, 92, pp.405~410 (2009)
44. Spigel DR, "Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab", J Clin Oncol, 28, pp.43~48 (2010)
45. Raje N, "Thalidomide : a revival story", N Engl J Med, 341, pp.1606~1609 (1999)
46. Lebrin F, "Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia", Nat Med, 16, pp.420~428 (2010)
47. Fanelli M, "Thalidomide: a new anticancer drug?", Expert Opin Investig Drugs, 12, pp.1211~1225 (2003)
48. Schiller JH, "A phase III trial of carboplatin, paclitaxel, and thoracic radiation therapy with or without thalidomide in patients with stage III non-small cell carcinoma of the lung (NSCLC): E3598", J Clin Oncol, 27(15s), pp.7503~ (2009)
49. Soda M, "Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer", Nature, 448, pp.561~566 (2007)
50. Sasaki T, "New strategies for treatment of ALK-rearranged non-small cell lung cancers", Clin Cancer Res, 17, pp.7213~7218 (2011)
51. Kwak EL, "Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer", N Engl J Med, 363, pp.1693~1703 (2010)
52. Romond EH, "Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer", N Engl J Med, 353, pp.1673~1684 (2005)
53. Dematteo RP, "Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour : a randomised, double-blind, placebo-controlled trial", Lancet, 373, pp.1097~104 (2009)
54. Tol J, "Monoclonal antibodies in the treatment of metastatic colorectal cancer : a review", Clin Ther, 32, pp.437~453 (2010)
55. 김정렬, "A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer", NEW ENGLAND JOURNAL OF MEDICINE, 351(27), pp.2817~2826 (2004), MASSACHUSETTS MEDICAL SOC
56. "Predictive genomic biomarkers" (2011)[URL]
57. Amann JM, "Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503", J Thorac Oncol, 5, pp.169~178 (2010)
58. Rosell R, "Screening for epidermal growth factor receptor mutations in lung cancer", N Engl J Med, 361, pp.958~967 (2009)
59. Bunn PA Jr, "Biomarkers are here to stay for clinical research and standard care", J Thorac Oncol, 5, pp.1113~1115 (2010)
60. Nguyen KS, "Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway", Clin Lung Cancer, 10, pp.281~289 (2009)
61. Engelman JA, "PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib", Cancer Res, 67, pp.11924~11932 (2007)
62. Jänne PA, "Phase I doseescalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors", Clin Cancer Res, 17, pp.1131~1139 (2011)
63. Janne PA, "Efficacy and safety of PF-00299804 (PF299) in patients (pt) with advanced NSCLC after failure of at least one prior chemotherapy regimen and prior treatment with erlotinib (E): a two-arm, phase II trial", J Clin Oncol, 27(15s), pp.8063~ (2009)
64. Schütze C, "Combination of EGFR", HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinoma, 2007, pp.183, 256~264
65. Yap TA, "Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors", J Clin Oncol, 28, pp.3965~3972 (2010)
66. Wong KK, "HKI-272 in non small cell lung cancer", Clin Cancer Res, 13(15 Pt 2), pp.s4593~s4596 (2007)
67. Wong KK, "A phase I study with neratinib(HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors", Clin Cancer Res, 15, pp.2552~2558 (2009)
68. Sequist LV, "Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor : results of a phase II trial in patients with advanced non-small-cell lung cancer", J Clin Oncol, 28, pp.3076~3083 (2010)
69. Chung EJ, "In vitro and in vivo radiosensitization with AZD6244(ARRY-142886), an inhibitor of mitogen-activated protein kinase", extracellular signal-regulated kinase 1, Clin Cancer Res, pp.2009, 15[DOI]
70. Shannon AM, "The mitogen-activated protein", extracellular signal-regulated kinase kinase 1, Clin Cancer Res, pp.2009, 15[DOI]
71. Hainsworth JD, "A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244(ARRY-142886)versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens", J Thorac Oncol, 5, pp.1630~1636 (2010)
72. Mross K, "Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors", Clin Cancer Res, 16, pp.311~319 (2010)
73. Reck M., "BIBF 1120 for the treatment of non-small cell lung cancer", Expert Opin Investig Drugs, 19, pp.789~794 (2010)

관련 논문AI추천